JP2008530137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530137A5 JP2008530137A5 JP2007555369A JP2007555369A JP2008530137A5 JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5 JP 2007555369 A JP2007555369 A JP 2007555369A JP 2007555369 A JP2007555369 A JP 2007555369A JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- skin
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 210000003491 skin Anatomy 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 3
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 206010037844 rash Diseases 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 206010040844 Skin exfoliation Diseases 0.000 claims 1
- 208000032509 Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum Diseases 0.000 claims 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65311405P | 2005-02-14 | 2005-02-14 | |
| US71676205P | 2005-09-13 | 2005-09-13 | |
| US74995205P | 2005-12-13 | 2005-12-13 | |
| PCT/US2006/005327 WO2006088955A2 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008530137A JP2008530137A (ja) | 2008-08-07 |
| JP2008530137A5 true JP2008530137A5 (cg-RX-API-DMAC7.html) | 2009-04-02 |
Family
ID=36685803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555370A Expired - Fee Related JP4927762B2 (ja) | 2005-02-14 | 2006-02-14 | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| JP2007555369A Pending JP2008530137A (ja) | 2005-02-14 | 2006-02-14 | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555370A Expired - Fee Related JP4927762B2 (ja) | 2005-02-14 | 2006-02-14 | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (11) | US20060188500A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1856150A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4927762B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2006214325B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2595877A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL184734A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2007009577A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2006088956A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| AU7445900A (en) | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
| SI2230299T1 (sl) | 2002-01-18 | 2012-07-31 | Zymogenetics Inc | Nov citokinski zcytor ligand |
| US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
| CA2594502A1 (en) * | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| AU2006214325B2 (en) * | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| CA2594490A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| JP2009528264A (ja) | 2006-01-10 | 2009-08-06 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| CA2654623C (en) | 2006-06-08 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease |
| PL2594586T3 (pl) * | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| US7799323B2 (en) * | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| MY185647A (en) * | 2007-12-05 | 2021-05-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| CA2708251C (en) | 2007-12-07 | 2016-04-12 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP5650871B1 (ja) * | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| HRP20250972T1 (hr) | 2015-04-14 | 2025-10-10 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak |
| MA43918A (fr) * | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| US10060273B2 (en) | 2015-04-15 | 2018-08-28 | United Technologies Corporation | System and method for manufacture of abrasive coating |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| CN112020511B (zh) | 2018-03-16 | 2025-07-04 | 硕腾服务有限责任公司 | 用于兽医用途的白介素-31单克隆抗体 |
| MA52011A (fr) | 2018-03-16 | 2021-01-20 | Zoetis Services Llc | Vaccins peptidiques contre l'interleukine-31 |
| JP2021522241A (ja) * | 2018-04-25 | 2021-08-30 | キニクサ ファーマシューティカルズ， リミテッド | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
| CN112190708B (zh) * | 2019-07-08 | 2023-09-05 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| RU2707181C1 (ru) * | 2019-08-15 | 2019-11-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови |
| EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| KR102392954B1 (ko) * | 2020-02-11 | 2022-05-02 | 연세대학교 산학협력단 | 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도 |
| WO2022049614A1 (ja) | 2020-09-01 | 2022-03-10 | 中外製薬株式会社 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| WO2003024484A1 (fr) * | 2001-09-14 | 2003-03-27 | Ono Pharmaceutical Co., Ltd. | Medicaments pour traiter le prurit |
| SI2230299T1 (sl) * | 2002-01-18 | 2012-07-31 | Zymogenetics Inc | Nov citokinski zcytor ligand |
| US7494804B2 (en) * | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
| JP2004219390A (ja) * | 2002-02-22 | 2004-08-05 | Taisho Pharmaceut Co Ltd | アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法 |
| KR20040083416A (ko) | 2002-02-22 | 2004-10-01 | 다이쇼 세이야꾸 가부시끼가이샤 | 지양제 |
| JP2004107209A (ja) * | 2002-09-13 | 2004-04-08 | Nippon Oruganon Kk | 掻痒治療薬 |
| JP4503942B2 (ja) * | 2003-06-11 | 2010-07-14 | 大正製薬株式会社 | 止痒剤 |
| WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
| CA2594502A1 (en) | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| AU2006214325B2 (en) * | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| CA2594490A1 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| WO2007037137A1 (ja) * | 2005-09-28 | 2007-04-05 | Konica Minolta Opto, Inc. | 射出成形装置 |
| JP2009528264A (ja) * | 2006-01-10 | 2009-08-06 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| PL2594586T3 (pl) * | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| US7799323B2 (en) | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| CA2708251C (en) * | 2007-12-07 | 2016-04-12 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
-
2006
- 2006-02-14 AU AU2006214325A patent/AU2006214325B2/en not_active Ceased
- 2006-02-14 MX MX2007009577A patent/MX2007009577A/es active IP Right Grant
- 2006-02-14 CA CA002595877A patent/CA2595877A1/en not_active Abandoned
- 2006-02-14 EP EP06735136A patent/EP1856150A2/en not_active Withdrawn
- 2006-02-14 US US11/353,454 patent/US20060188500A1/en not_active Abandoned
- 2006-02-14 MX MX2007009471A patent/MX2007009471A/es not_active Application Discontinuation
- 2006-02-14 JP JP2007555370A patent/JP4927762B2/ja not_active Expired - Fee Related
- 2006-02-14 JP JP2007555369A patent/JP2008530137A/ja active Pending
- 2006-02-14 US US11/353,427 patent/US20060188499A1/en not_active Abandoned
- 2006-02-14 EP EP06735137.9A patent/EP1856539B1/en not_active Not-in-force
- 2006-02-14 CA CA2595939A patent/CA2595939C/en not_active Expired - Fee Related
- 2006-02-14 AU AU2006214326A patent/AU2006214326B2/en not_active Ceased
- 2006-02-14 WO PCT/US2006/005328 patent/WO2006088956A2/en not_active Ceased
- 2006-02-14 WO PCT/US2006/005327 patent/WO2006088955A2/en not_active Ceased
-
2007
- 2007-07-19 IL IL184734A patent/IL184734A/en not_active IP Right Cessation
- 2007-07-23 IL IL184776A patent/IL184776A/en not_active IP Right Cessation
-
2008
- 2008-09-26 US US12/239,107 patent/US7723048B2/en active Active
-
2009
- 2009-07-02 US US12/497,383 patent/US20090280121A1/en not_active Abandoned
-
2010
- 2010-03-19 US US12/727,912 patent/US8435745B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 US US13/094,482 patent/US8388964B2/en not_active Expired - Fee Related
-
2012
- 2012-04-15 IL IL219145A patent/IL219145A0/en unknown
-
2013
- 2013-01-30 US US13/754,278 patent/US20130177563A1/en not_active Abandoned
- 2013-03-13 US US13/799,048 patent/US8926957B2/en active Active
-
2015
- 2015-10-09 US US14/879,550 patent/US20160024201A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,774 patent/US20170096484A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,883 patent/US20190040125A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008530137A5 (cg-RX-API-DMAC7.html) | ||
| JP2008530138A5 (cg-RX-API-DMAC7.html) | ||
| US11446398B2 (en) | Regulated biocircuit systems | |
| Kumari et al. | Curcumin inhibits lipopolysaccharide (LPS)-induced endotoxemia and airway inflammation through modulation of sequential release of inflammatory mediators (TNF-α and TGF-β1) in murine model | |
| JP2020022469A (ja) | 血中循環腫瘍細胞に関する方法およびアッセイ | |
| BR112014010161A2 (pt) | anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43 | |
| US11912994B2 (en) | Methods for reactivating genes on the inactive X chromosome | |
| RU2013153592A (ru) | Анти-mif антитела | |
| US11059906B2 (en) | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma | |
| AU2005265067B2 (en) | Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors | |
| KR20200106053A (ko) | Atr 억제제를 사용한 암 치료 방법 | |
| JP2022531838A (ja) | 慢性炎症およびウイルス感染の診断と治療 | |
| Kim et al. | Hedgehog signaling is associated with liver response to fractionated irradiation in mice | |
| IL272418B1 (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| Papismadov et al. | p21 regulates expression of ECM components and promotes pulmonary fibrosis via CDK4 and Rb | |
| WO2010036031A3 (en) | Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same | |
| CN102641501B (zh) | Nalp3-asc炎症复合体及其激活抑制剂在制备朊病毒病药物中的应用 | |
| Mahmoud et al. | Aptabinding of tumor necrosis factor‐α (TNFα) inhibits its proinflammatory effects and alleviates islet inflammation | |
| Dou et al. | Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR‐Mediated JAK/STAT Signaling and Immune Modulation | |
| MX2014014290A (es) | Anticuerpos anti - ccl2 para el tratamiento de la esclerodermia. | |
| KR102202120B1 (ko) | 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도 | |
| TWI672319B (zh) | 用於確認、預測以及治療癌症的方法 | |
| SCHREIBER | RESTORATION OF TRANSCRIPTIONALLY ACTIVE CHROMATIN AT FXN IN FRDA iPSC-DIFFERENTIATED NEURON PROGENITOR CELLS FOLLOWING PHARMACOLOGICAL INTERVENTION | |
| Boonto et al. | Deciphering the role of taurine-upregulated gene 1 in liver diseases: Mechanisms, clinical relevance, and emerging therapeutic opportunities | |
| EP4630818A1 (en) | Methods of treating aml by identifying and targeting a myeloid/lymphoid leukemia stem cell |